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AKR1D1*36 C>T (rs1872930) allelic variant is associated with 
variability of the CYP2C9 genotype predicted pharmacokinetics 
of ibuprofen enantiomers – a pilot study in healthy volunteers
The relative contribution of CYP2C9 allelic variants to 
the pharmacokinetics (PK) of ibuprofen (IBP) enantio-
mers has been studied extensively, but the potential 
clinical benefit of pharmacogenetically guided IBP treat-
ment is not evident yet. The role of AKR1D1*36C>T (rs 
1872930) allelic variant in interindividual variability of 
CYP450 mediated drug metabolism was recently eluci-
dated. A total of 27 healthy male subjects, volunteers in 
IBP single-dose two-way cross-over bioequivalence 
studies were genotyped for CYP2C9*2, CYP2C9*3 and 
AKR1D1*36 polymorphisms. The correlation between 
CYP2C9 and AKR1D1 genetic profile and the PK param-
eters for S-(+) and R-(–)-IBP was evaluated. Remarkable 
changes in the PK values pointing to reduced CYP2C9 
enzyme activity were detected only in the CYP2C9*2 al-
lelic variant carriers. Statistically significant association 
between the AKR1D1*36 allele and the increased IBP me-
tabolism (low AUC0-t and 0–∞, high Cltot and short tmax val-
ues for both enantiomers) was observed in subjects car-
rying the CYP2C9 *1/*3 or CYP2C9*1/*1 genotype. The 
clinical value of concomitant CYP2C9 and AKR1D1 ge-
notyping has to be further verified.
Keywords: ibuprofen, enantiomers, pharmacokinetics, 
AKR1D1, CYP2C9, pharmacogenetics
Ibuprofen (IBP, 2-arylpropionic acid derivative [(R,S)-2-(4-(2-methylpropyl)phenyl)] 
propionic acid]) is probably the most widely used non-steroid anti-inflammatory drug 
(NSAID) today. Its short plasma half-life, wide therapeutic window, lack of development 
of pathologically-related metabolites and prolonged retention in specific body compart-
ments make IBP one of the safest and probably the least toxic non-selective inhibitors of 
cyclooxygenase (COX-1 and COX-2) and the only NSAID approved for use in pediatric 
population starting from the age of 3 months (1, 2). In most formulations, IBP exists as a 
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diastereoisomeric mixture, which comprises a S-(+) moiety and a R-(–)enantiomer moiety. 
S-(+)-IBP is pharmacologically more active as a prostaglandin (PG) synthesis inhibitor; 
however, R-(–)-IBP has pharmacological properties relevant to the anti-inflammatory ac-
tivity of IBP. In humans, R-(–)-IBP undergoes extensive enantiomeric conversion to the S-(+) 
isomer and both isomers are metabolized extensively to inactive metabolites. Thus, the 
contribution of each of the isomers to the anti-inflammatory, analgesic and antipyretic 
effects of IBP underlines the interrelation between the PK/metabolism of IBP and its phar-
macodynamics (PD) (1, 3, 4). When orally administered, IBP is rapidly absorbed from the 
upper gastrointestinal tract, with the maximum time to reach the maximum plasma con-
centration (tmax) of approximately 1–2 h. Depending on the release characteristics of the 
formulation, various plasma S/R ratios have been observed, namely, higher with modified-
-release compared to conventional release, i.e. immediate-release formulations. The bio 
distribution of IBP is characterized by high plasma protein binding and low distribution 
volume (Vd), with significant accumulation in inflamed compartments. In subjects with 
preserved renal and liver functions, IBP exhibits linear kinetics when taken in up to 1200 
mg (repeated) doses. Plasma concentration (Cp) and, to some extent, the area under the 
curve (AUC) values are dose-related, but with little variation with (repeated) dosage as 
suggested by the kinetic constants, elimination half-life (t1/2)/elimination rate constant (Kel). 
The non-linear PKs occurring at high doses is due to the saturation of plasma protein bind-
ing. The plasma half-life of IBP is between 2 and 3 h on average, with excretion being 
complete after 24 h of the last IBP dose administration. The relatively fast rate of absorption 
of IBP is followed by a systematic metabolism of both enantiomers, which are extensively 
(99 %) metabolized to their major chiral, pharmacologically inactive 2-hydroxyl, 2-car-
boxyl and glucuronide metabolites via CYP450 (CYP2C8 and 2C9) mediated oxidation and 
UGT (UGT2B7) mediated glucuronidation. Half-lives of the S-(+)-IBP, 2-hydroxylated or 
carboxylated glucuronides are approximately 3.7 h and about 1.7 h (1,5–8) of R-(–)-IBP acyl 
glucuronides. CYP2C9 has been identified as the most important catalyst for the formation 
of all oxidative metabolites of IBP enantiomers, though it is mainly involved in the hydroxy-
lation of S-(+)-IBP, while CYP2C8 preferentially metabolizes R-(–)-IBP (8–10). Polymor-
phisms in CYP2C8 and CYP2C9 gene (*2 and *3 allelic variants) coding for the correspond-
ing enzymes are among the identified factors with a direct impact on the PK of IBP and 
thus on the variability in drug response and adverse drug events (11). Major adverse events 
affect the gastrointestinal tract (GIT), kidneys and the coagulation system. Chronic treat-
ment with IBP is a potential reason for the occurrence of GI bleeding, increased risk of 
gastric ulcers and damages and also of epistaxis, heart failure, hyperkalemia, confusion 
and bronchial spasms. Other adverse reactions, though very rare, were also reported, 
 including renal adverse events such as acute renal failure, interstitial nephritis and  nephritic 
syndrome (12–15). The incidence and intensity of ADE might vary significantly due to the 
CYP2C8/C9 stereospecific preference of IBP (11). However, information on interindividual 
variability of pharmacokinetic parameters related to the safety profile of IBP and its enan-
tiomers is limited. Published results on the CYP2C8/C9 genetic impact on IBP metabolism 
are mainly inconclusive and open to doubt, mostly because of the incomplete genotype 
effect observed in studies with small healthy cohorts and/or heterogeneous cohorts and 
also because of the difficulty to distinguish the CYP2C8/C9 allelic variant effects on the IBP 
enantiospecific metabolism due to the high sequence homology between the two genes 
(16–18). Moreover, it has been found that the amount of active CYP2C9 enzyme depends 
on the level of gene expression, the rates of mRNA transcription and degradation, protein 
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degradation, the presence of enzyme inhibitors/antagonists and post-transcriptional 
 regulation of CYP2C isoforms by microRNAs. The amount of protein of other CYP iso-
forms (CYP2D6, CYP3A4) might also influence CYP2C9 enzyme activity via  protein-protein 
interactions (19). In addition, the acylation of proteins to form adducts from the reaction of 
acyl glucuronides of ibuprofen may be of relevance for adverse reactions in the liver anal-
ogous to those occurring with some other NSAIDs, though evidence for this is still lacking 
(1). Overall, even when CYP2C9 enzyme involvement is major, each COX inhibitor has to 
be evaluated on an individual basis, taking into account the available data related to all 
clearance mechanisms, direct conjugation and especially non-P450  oxidation (20). 
A recently published study by Chandry et al. (21) provided a new insight, which can 
account for interindividual differences in CYP450 drug metabolism, drug efficacy and 
adverse drug events. The authors obtained experimental evidence supporting the putative 
role of the AKR1D1 gene as a trans-genetic regulator of the CYP network and pointed to 
the significant association between AKR1D1*36 C>T (rs1872930) allelic variation, augmented 
hepatic CYP450 mRNA expression and increased activity of AKR1D1, CYP2C9 and 
 CYP2C8 enzymes coded by the corresponding genes. AKR1D1 catalyzes the NADPH 
 dependent reduction of bile acids and steroids but it is also involved in the reduction of 
either carbonyl groups or α,β-unsaturated ketones on a variety of xenobiotics (dicarbonyls 
and polycyclic aromatic hydrocarbon trans-dihydrodiols, including a great variety of non-
steroidal aldehydes and ketones (22). Hence, it is plausible that the AKR1D1*36 C>T 
(rs1872930) polymorphism may contribute to the observed interindividual variability of 
IBP PK and the associated drug response. These recent findings are of particular impor-
tance since the most common CYP2C8/C9 cis-variations, independently and together, do 
not explain clearly the patient-to-patient inconsistency in the metabolism of IBP enantio-
mers. Despite the availability of numerous studies evaluating the genetic factors associ-
ated with interindividual variability of the IBP metabolism, there are no reported studies 
about the impact of AKR1D1*36C>T on the metabolism of S-(+) and R-(–)-IBP. Having all 
this in mind, our pilot study aims to evaluate the separate and appraise the combined 
genetic impact of CYP2C9 and AKR1D1 variant alleles on the pharmacokinetics of ibuprofen 
enantiomers in healthy male volunteers from The Republic of Macedonia.
EXPERIMENTAL
Study population
The study sample comprised 27 healthy Caucasian male volunteers according to the 
medical history, ECG, vital signs, laboratory data and physical examination (non-smokers, 
aged 18–55 years, mean weight 81.4 ± 10.61 kg, BMI between 18.5 and 30.0 kg m–2), enrolled 
in four bioequivalence trials. Investigations were conducted in the Department of Pre-
clinical and Clinical Toxicology and Pharmacology of the Faculty of Medicine (University 
“Ss Cyril and Methodius” in Skopje, Macedonia) after the approval of the Faculty of Medi-
cine Ethics and Scientific Committee and authorization by the local regulatory agency. All 
studies were performed in accordance with the local legislation on clinical research in 
humans and the Helsinki Declaration (2013), following the Guidance on Good Clinical 
Practice (Note for Guidance on Good Clinical Practice; ЕМА/CHMP/ICH/135/95 London. 
June 2017), Guidance on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 
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Rev. London. January 2010) and EMA Ibuprofen oral use immediate release formulations 
200–800 mg product-specific bioequivalence guidance (EMA/CHMP/356876/2017).
None of the participants were related; they were fully informed about the nature of 
both PK and pharmacogenetic (PGx) studies, gave their written informed consent and could 
discontinue their participation at any time during the trials. None of the subjects partici-
pated in more than one trial. The exclusion criteria of interest were clinically significant 
illnesses and surgery within 4 weeks prior to the first dosing; clinically significant abnor-
malities of medical history (neurological, endocrinal, cardiovascular, pulmonary, hemato-
logical, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic diseases) 
at physical examination, of the ECG, of hematology, biochemistry or urinalysis results; his-
tory of hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response 
to aspirin or other NSAIDs; history of recurrent peptic ulcer/hemorrhage; history of GI 
disease (ulcerative colitis, Crohn’s disease); history of GI bleeding or perforation related to 
previous NSAID therapy; positive alcohol test at Check-in (Day-1) and history of alcohol 
and/or drug abuse within one year prior to the screening; use of investigational drugs within 
28 days (4 weeks) or any drugs known to induce or inhibit hepatic drug metabolism within 
28 days (4 weeks) prior to the first administration of the study medication and participation 
in other clinical studies within 2 months before the study.
Bioequivalence trials design and procedures
All four IBP bioequivalence trials were designed as single-center, randomized, open-
-label, two-way cross-over bioequivalence studies of the oral, immediate-release formula-
tion of IBP with systemic action (with identical contents of both enantiomers), following a 
single dose administration under fasting conditions. The IBP plasma concentrations of 12 
subjects receiving 400 mg, 10 subjects participating in the studies with 375 mg, 2 subjects 
receiving 200 mg and 3 subjects receiving 100 mg oral IBP were used in the PK analysis. 
According to the study protocols, a total of 20 blood samples were collected in each period: 
pre-dose and 0.083, 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 14 
hours post-dose. An additional blood sample was collected at Check-in (Day-1) of Period 1 
for the investigation of potential pre-dose concentrations and this sample was not used for 
pharmacokinetic evaluation. The subjects remained at the clinical unit during the whole 
period, i.e. until the collection of the 14 h post drug blood sample. The samples were cen-
trifuged at 4 °C for 10 min at 3500 rpm and plasma aliquots (labeled with the protocol code, 
the subject number, the period and the time at which the sample was obtained) were 
stored at –30 °C until further analytic determinations.
Pharmacokinetic analysis
Concentrations of R-(–)-IBP and S-(+)-IBP were determined using validated high-per-
formance liquid chromatography coupled with a tandem mass spectrometry detection 
(HPLC MS/MS) chiral method according to Nakov et al. (23). Estimation of the PK para-
meters was performed from the plasma concentration-time dependent data by a standard 
non-compartmental method using Pharsight® Knowledgebase ServerTM and Phoenix® 
WinNonlin®. Maximum plasma concentration (cmax) and tmax were obtained directly from 
raw data. The area under the curve to the last measured concentration (AUC0–t) was calcu-
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lated by linear trapezoidal integration. The area under the curve extrapolated to infinity 
(AUC0–∞) was calculated as the sum of AUC0–t and the residual area (ct divided by Kel, with 
ct as the last measured concentration and Kel as the elimination rate constant). Because of 
different doses administered in different trials, AUC and cmax were divided by the dose 
according to the body weight (mg kg–1) of each subject. The elimination half-life (t1/2) was 
calculated as 0.693 Kel–1. Total drug clearance adjusted for bioavailability (Cltot) was calcu-
lated by dividing the dose by AUC and weight-adjusting.
CYP2C9 and AKR1D1 genotyping
Genomic DNA was isolated from 3 mL whole blood (collected in an EDTA blood tube) 
using proteinase K digestion/phenol-chloroform extraction and ethanol precipitation and 
stored at 4 °C until genotyping. The obtained DNA was spectrophotometrically quantified 
on Nano Drop® and its purity was verified using a 260/280 nm ratio. DNA integrity was 
confirmed by 0.8 % agarose electrophoresis, stained with ethidium bromide. Identification 
of CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910) and AKR1D1*36C>T (rs1872930) variant al-
leles was done with a real-time polymerase chain reaction [MxPro 3005P, Stratagene, La 
Jolla, CA, USA] using TaqMan SNP and drug metabolism genotyping assays according to 
the manufacturers’ instructions [Applied Biosystems, Foster City, CA, USA]. The CYP2C9 
and AKR1D1 genotyping was performed at the Center for Biomolecular and Pharmaceutical 
Analysis, Faculty of Pharmacy, University “Ss Cyril and Methodius” in Skopje, Macedonia.
Statistical analysis
The Hardy-Weinberg equilibrium was estimated for all analyzed variants. Deviations 
from the equilibrium were detected by comparing the observed and expected frequencies 
using Fisher’s exact test. Pearson’s chi-square test was used for evaluation of differences in 
the CYP2C9 and AKR1D1 allelic and genotypic frequencies between the study subjects 
and those reported for the Macedonian population. Values of PK parameters were ex-
pressed as mean ± SD. All statistical analyses were performed using MedCalc 14.12.0 and 
StatGraph17.1.03 software packages. Differences in PK parameters among individuals with 
different genotypes were assessed with the Kruskal-Wallis test and Dunn test for post hoc 
analysis. Odds ratios [OR] were calculated with 95 % confidence limits [95 % CI]. Factors 
with p ≤ 0.05 were considered statistically significant.
RESULTS AND DISCUSION
Pharmacokinetic parameters
Interindividual variability in the PK parameters for IBP enantiomers, present at iden-
tical concentrations in the administered racemic product, was investigated in 27 healthy 
volunteers. Mean values of the PK parameters are summarized in Table I. Although the 
mean AUC0-inf for S-(+)-IBP was slightly higher compared to the mean value for R-(–)-IBP 
(49.985 mg h L–1 vs. 42.606 mg h L–1, respectively), we could not confirm the one-way chiral 
conversion of R-(–) to S-(+) from previously published data (5), most probably because of 
the small sample size. High interindividual variability for both S-(+) and R-(–)-IBP regard-
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ing Cltot and cmax was observed. Variation of Cltot and cmax (interval between the minimal 
and maximal value) for S-(+)-IBP was 2.56–13.47 L h–1 and 5.36–24.35 mg L–1; while it was 
3.74–16.70 L h–1 and 1.07–22.01 mg L–1, respectively, for R-(–)-IBP. As a result, high interin-
dividual variability was also observed for AUC 0-inf ranging between 25.38–109.93 mg h L–1 
or S-(+)-IBP and 16.65–76.87 mg h L–1 for R-(–)-IBP.
Table I. Summary of pharmacokinetic parameters for S-(+) and R-(–)-IBP enantiomers in healthy volunteers
PK parameters
Ibuprofen enantiomers (N = 27)
S-(+)-IBP R-(–)-IBP
Mean ± SD 95 % CI Mean ± SD 95 % CI
AUC0-t(mgh L–1) 48.335 ± 19.854 44.512–52.159 42.173 ± 17.861 38.733–45.613
AUC0–∞(mg h L–1) 49.985 ± 21.408 45.862–54.108 42.606 ± 17.904 39.157–46.054
Cltot (L h–1) 7.219 ± 2.824 6.675–7.763 8.460 ± 3.210 7.842–9.078
cmax(mg L–1) 12.691 ± 3.939 11.932–13.449 13.108 ± 4.439 12.253–13.963
Kel(L h–1) 0.276 ± 0.0351 0.269–0.283 0.403 ± 0.105 0.383–0.424
tmax(h) 2.558 ± 0.379 2.485–2.631 0.965 ± 0.669 0.836–1.094
t1/2(h) 1.089 ± 0.691 0.956–1.223 1.856 ± 0.573 1.745–1.966
Fig. 1. Time dependent, dose corrected plasma concentrations of a) S-(+)-IBP and b) R-(–)-IBP after 
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Genotyping for CYP2C9 and AKR1D1 alleles
CYP2C9 and AKR1D1 allelic frequencies and genotype distributions in the consid-
ered population of healthy volunteers (N = 27 subjects) are presented in Table II. All inves-
tigated genetic variants (CYP2C9*2, CYP2C9*3 and AKR1D1*36C>T) were in Hardy-Wein-
berg equilibrium (p = 0.558, p = 0.639, p = 0.936, respectively) and their frequencies were in 
accord with those reported for the population of The Republic of Macedonia (p = 0.342 for 
CYP2C9*2, p = 1 for CYP2C9*3 and p = 0.664 for AKR1D1*36C>T) (24, 25). No homozygosity 
for the variant CYP2C9 *2 and *3 alleles (*2/*2 and *3/*3 genotype) was detected and none 
of the subjects was identified as a carrier of both CYP2C9 variant alleles (*2/*3 genotype) 
in this study. This finding was expected taking into account the small sample size as well 
as the fact that the prevalence of these functionally significant genotypes in most popula-
tions, including the Macedonian, is below 0.05.
Evaluation of CYP2C9 PGx/PK relationship
The time dependent plasma concentration curves of both IBP enantiomers according 
to the CYP2C9 genotype are shown in Fig. 1. The observed effects were similar to previ-
ously published reports (9, 26–28), suggesting that both CYP2C9 *2 and *3 alleles reduce 
enzyme activity. Pharmacokinetic parameters derived from a non-compartmental analysis 
of individual data are presented in Table III. Significant differences across the three geno-
type groups regarding S-(+)-IBP for AUC0-t (p = 0.016), AUC0–∞ (p = 0.019), Cltot (p = 0.022) and 
cmax (p = 0.039) were observed. Pairwise comparisons revealed that the subjects with the 
CYP2C9 *1/*2 genotype had 25 % lower Cltot and 14 % higher cmax compared to subjects 
with the CYP2C9 *1/*1 CYP2C9 *1/*3 genotype. CYP2C9 *1/*2 had markedly higher AUC0-t 
and AUC0–∞ values (25 % higher) than those found for CYP2C9*1/*1.
In case of R-(−)-IBP, significant differences across the three genotype groups regarding 
Cltot (p = 0.001), cmax (p = 0.023), Kel (p = 0.024) and t1/2 (p = 0.024) were identified. Pairwise 
Table II. Genotype distribution and allelic frequencies of CYP2C9 and AKR1D1genetic variants in the study 
population of healthy volunteers
Genotype n
Frequencies
Allele n Frequencies 
observed expected
CYP2C9
*1/*1 18 0.667 0.694
*1 45 0.833
*1/*2 5 0.185 0.154
*1/*3 4 0.148 0.123
*2 5 0.093
*2/*2 0 0.000 0.009
*3/*3 0 0.000 0.005
*3 4 0.074
*2/*3 0 0.000 0.014
AKR1D1
*1/*1 14 0.519 0.522
*1 39 0.722
*1/*36 11 0.407 0.401
*36/*36 2 0.074 0.077 *36 15 0.278
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comparisons revealed that the heterozy-
gote carriers of CYP2C9 *3 allele had a 16 
% increase in Cltot and 21 % decrease in 
cmax in comparison with the carriers of 
CYP2C9 *2 or CYP2C9 *1/*1 genotype. In 
addition, the CYP2C9 *2 allele was asso-
ciated with 25 % higher Kel and 10 % low-
er t1/2 values compared to subjects carry-
ing the CYP2C9 *1/*1 genotype. For both 
IBU enantiomers, tmax was the only phar-
macokinetic parameter not associated 
with any of the CYP2C9 polymorphic al-
leles. Based on the results of our research, 
both CYP2C9 *2 and *3 polymorphisms 
have to be considered as factors associated 
with a change in PK parameters of IBP. 
Still, unlike other studies (9, 16, 27), our 
data suggest a stronger impact on IBP PK 
for CYP2C9 *2 compared to the CYP2C9*3 
allele. This might be attributed to the un-
derrepresentation of homozygotes for the 
variant alleles (*2/*2;*3/*3 and *2/*3 geno-
types) considering that changes in PK 
parameters are proportional to the num-
ber of CYP2C9 variant alleles (20). More-
over, they suggest that even though CY-
P2C9 is considered a major genetic factor 
for R-(–) and S-(+)-IBP clearance, the effect 
of CYP2C8 should also be measured 
since CYP2C8 *3 alone or in combination 
with CYP2C9 *2 has a more significant 
impact on IBP AUC and clearance than 
CYP2C9 *3 (26, 27, 29, 30). Bearing in 
mind the high sequence homology be-
tween CYP2C9 and CYP2C8 as well as 
the recognized LD between the CY-
P2C8*3 and CYP2C9*2 alleles; where 96 
% of the subjects with the CYP2C8*3 al-
lele also carry CYP2C9*2 and 85 % of the 
subjects with CYP2C9*2 variant also 
have a CYP2C8*3 (17, 18), we did not as-
sess the effect of CYP2C8 polymorphism 
on IBP enantiomeric metabolism. How-
ever, the results obtained are in agree-
ment with those previously reported by 
Rodrigues and Rushmore (31), which 
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CYP2C9 genotype status, there is no significant difference in IBP PK parameters between 
subjects genotyped as CYP2C9 *1/*3 and *1/*1.
Although the differences observed in PK parameters, especially clearance, after oral 
administration in subjects with different CYP2C9 genotypes (dominantly carriers of CY-
P2C9 *2/*2; *2/*3 and *3/*3), suggest that the safety and efficacy of CYP2C9 substrates could 
be improved by drug dose adjustment (32, 33) and since the correlation between the geno-
type and phenotype is not clear, prospective evaluations of this strategy are needed before 
establishing its clinical utility.
Evaluation of AKR1D1 PGx/PK relationship
Data regarding the impact of the AKR1D1 genetic variant on the IBP enantiomeric meta-
bolism are summarized in Table IV. Careers of *36 allele had significantly higher Cltot and 
notably shorter tmax for both IBU enantiomers compared to wild type carriers (p < 0.001). 
Furthermore, AKR1D1 *36 allele was associated with significantly lower AUC(0-t and 0–∞) val-
ues but only in regard to S-(+)-IBP. We observed that the increased AKR1D1 enzyme activity 
in the metabolic biotransformation of IBU enantiomers was not proportional to the number 
of *36 variant alleles. For S-(+)-IBP, the genotype model of analysis showed significant differ-
ences across the three genotype groups regarding AUC0-t and AUC0–∞ (p < 0.001, for all), Cltot 
and tmax (p < 0.001). The post hoc Dunn test revealed that the AKR1D1 *1/*36 genotype was 
associated with higher Cltot and shorter tmax values compared to the AKR1D1 *36/*36 geno-
type and lower AUC (0-t and 0–∞) values than those found for AKR1D1 *1/*1 and AKR1D1 
*36/*36 genotypes. The same pattern of significant alterations (p < 0.001) regarding AUC(0-t and 
0–∞), Cltot and tmax across the three genotypes was observed for R-(−)-IBP.
Since we had established previously that CYP2C9 *2 had a marked effect on IBP PK 
while the effect of *3 allele was indistinct, we supposed that the CYP2C9 genotype con-
founded the association between AKR1D1*36 and IBP PK parameters. Therefore, an addi-
tional analysis was performed to assess the impact of the AKR1D1 *36 variant allele but only 
in subjects who are not carriers of the CYP2C9 *2 allele (Table V). In these subjects, the car-
riers of AKR1D1*36 allele had significantly lower AUC(0-t and 0–∞), higher Cltot and shorter tmax 
values for both S-(+)-IBP and R-(–)-IBP. Interestingly, in this sub-stratification analysis, the 
differences for IBP PK parameters were proportional to the number of the AKR1D1*36 al-
leles. A statistically significant variation across the three genotypes regarding AUC(0-t and 0–∞) 
Cltot and tmax (p < 0.001) was found for both IBP enantiomers. Pairwise comparisons showed 
that the AKR1D1 *36/*36 genotype was associated with increased metabolic biotransforma-
tion of IBP compared to other AKR1D1 genotypes. These results confirmed our initial as-
sumption regarding the clear influence of the CYP2C9*2 allelic variant on IBP PKs and high-
lights the distinct role of AKR1D1*36C>Т in the metabolism of IBP.
The present study is the first to investigate the relationship between AKR1D1*36C>T 
(rs1872930) and the combined AKR1D1/CYP2C9 effect on the PK of IBP enantiomers. Re-
garding the contribution to previous knowledge (19, 21) and our expectations, it is still 
unclear whether the AKR1D1*36 C>T (rs1872930) allelic variant influences CYP2C9 enzyme 
activity (i.e. catalytic activity, kinetics), or the expression of CYP2C9 mRNA, and conse-
quently enzyme activity. Future studies specifically designed to answer this questions of 
broader biological relevance would be very interesting. However, the results obtained in 
the present study support the data published by Chaundry et al. (21) and Tracy et al. (19) 
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and add to the evidence that genetic variation in genes, like AKR1D1, is an important 
contributor to variation in CYP450 activity, by influencing the level of ligands that activate 
nuclear receptors responsible for the transcriptional regulation of P450s (e.g., bile acids).
In this report, we provide evidence for the association between CYP2C9 cis-allelic 
variants, AKR1D1 trans-genetic regulator of CYP450 gene network and the PK profile of 
IBP enantiomers. A crucial observation from the study is the association between the 
AKR1D1 minor allele and the increased IBP metabolism in subjects who are carriers of 
CYP2C9 *1/*3 or CYP2C9 wild genotype. Our model implies that patients on a long-term 
IBP treatment who are not carriers of CYP2C9*2 allele require additional stratification 
according to the AKR1D1 genotype in order to avoid the risk of adverse IBP side events. A 
potential weakness of the current study is the small number of subjects. In the next phase 
of the project, we will further evaluate the value of concomitant CYP2C9 and AKR1D1 
genotyping and conduct a reanalysis in a larger cohort of subjects with a higher represen-
tation of CYP2C8/C9 genotypes.
CONCLUSSIONS
The results from this pilot study contribute to the efforts aimed at clearer elucidation 
of the ibuprofen metabolic phenotype. They suggest that significant changes in the PK 
values associated with reduced CYP2C9 enzyme activity are anticipated to occur only in 
the carriers of the CYP2C9*2 allelic variant. AKR1D1*36 provides a new insight regarding 
the interindividual differences in the metabolism of the IBP enantiomers. The value of 
concomitant CYP2C9 and AKR1D1 genotyping has to be further proven in studies with a 
larger sample size and in prospective randomized clinical studies.
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